Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Breast Cancer Res Treat. 2019 Feb 12;175(2):297–303. doi: 10.1007/s10549-019-05158-3

Table 2.

Effects of Demographic and Clinical Characteristics (including UGT2B17) on Baseline BMD and BTM

	S	Bone Mineral Density (T-score)				Bone Turnover Markers
		Hip		Spine		Serum BAP		Urine NTx
		mean (std)	p-value	mean (std)	p-value	mean (std)	p-value	mean (std)	p-value
Race	White	0.19 (7.20)	0.97	0.25 (7.21)	0.08	22.81 (10.53)	0.18	349.51 (305.99)	0.29
	Black	−0.33 (0.66)		−0.62 (1.26)		24.64 (10.28)		356.72 (267.16)
	Other	1.37 (7.43)		−1.11 (1.25)		25.55 (8.05)		281.61 (152.73)
Chemo	Yes	0.27 (7.20)	0.54	0.16 (7.10)	0.73	24.17 (11.11)	0.06	363.83 (278.39)	0.12
Chemo	No	0.10 (6.58)	0.54	0.11 (6.54)	0.73	22.09 (9.80)	0.06	334.87 (315.44)	0.12
Tamoxifen	Yes	0.31 (7.84)	0.4	0.26 (7.91)	0.88	21.46 (9.37)	0.04	320.43 (289.54)	0.12
Tamoxifen	No	0.10 (6.28)	0.4	0.07 (6.11)	0.88	23.80 (10.75)	0.04	361.89 (303.65)	0.12
Drug	Letrozole	0.29 (6.98)	0.59	0.19 (6.80)	0.7	23.41 (11.29)	0.96	379.27 (324.50)	0.08
Drug	Exemestane	0.06 (6.76)	0.59	0.07 (6.80)	0.7	22.67 (9.55)	0.96	317.73 (269.43)	0.08
UGT2B17 Genotype	1/1	0.75 (9.79)	0.01	0.80 (9.80)	0.0076	22.05 (9.39)	0.35	330.34 (271.60)	0.66
	1/2	−0.37 (0.99)		−0.35 (1.56)		23.73 (11.40)		370.37 (340.39)
	2/2	−0.17 (4.05)		−0.85 (1.15)		24.54 (10.52)		331.66 (222.16)

Bold denotes associations significant at the p<0.05 level.